The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2019
Filed:
Oct. 05, 2011
Clifford Shone, Salisbury, GB;
April Roberts, Salisbury, GB;
Helen Ahern, Salisbury, GB;
Michael Maynard-smith, Salisbury, GB;
John Landon, Newcastle Emlyn, GB;
Clifford Shone, Salisbury, GB;
April Roberts, Salisbury, GB;
Helen Ahern, Salisbury, GB;
Michael Maynard-Smith, Salisbury, GB;
John Landon, Newcastle Emlyn, GB;
THE SECRETARY OF STATE FOR HEALTH, London, GB;
MICROPHARM LIMITED, Carmarthenshire, GB;
Abstract
The present invention relates to recombinantantigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of aToxin A sequence or residues 1500-1851 of aToxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of aToxin A sequence or within amino acid residues 1852-2366 of aToxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of aToxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of aToxin B. Also provided is the use of said antigens for the prevention/treatment/suppression ofinfection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.